The BioPharm Brief: Triple Threats, TL1A Bets, and AI Brains

Jun 22, 10:10 PM
Headliner
Share
Subscribe

Innovent advances a trispecific antibody into Phase 3 multiple myeloma testing, Bionyra enters the crowded TL1A race in inflammatory bowel disease, and Insilico Medicine partners with SK Biopharmaceuticals to apply AI to neuroimmune and CNS drug discovery.

Share
Subscribe
Next
The BioPharm Brief: FDA Decisions, Vaccine Momentum, and Lymphoma Advances
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief